"As the country's health care system is dealing with the unprecedented Covid-19 pandemic, we made the difficult decision to delay commercialization of Zeposia," the pharma company said in a written statement. "At Bristol Myers Squibb, our decisions will continue to be guided by what's in the best health interest of our patients, customers and employees."